Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5–10% and >10%, respectively. This risk assessment strategy awaits validation. We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation. Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups. An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several European registries have since validated the ESC/ERS risk status model; however, it is unknown if the ESC/ERS tool predicts clinical worsening or hospitalizations.(288)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [288]
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationAuthors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationMacitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Self-citationInitial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè, N., Barberà, J. A., Frost, A. E., Ghofrani, H.-A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J.-L., Grünig, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413687 · Cited by 1,182
Self-citationSelexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Self-citationBenza, R. L., Gomberg-Maitland, M., Miller, D. P., Frost, A., Frantz, R. P., Foreman, A. J., Badesch, D. B., & McGoon, M. D. (2012) · Chest · doi:10.1378/chest.11-0676 · Cited by 557
Kylhammar, D., Kjellström, B., Hjalmarsson, C., Jansson, K., Nisell, M., Söderberg, S., Wikström, G., & Rådegran, G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx257 · Cited by 540
Hoeper, M. M., Huscher, D., Ghofrani, H. A., Delcroix, M., Distler, O., Schweiger, C., Grunig, E., Staehler, G., Rosenkranz, S., Halank, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.026 · Cited by 466
Self-citationUpfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Sitbon, O., Jaïs, X., Savale, L., Cottin, V., Bergot, E., Macari, E. A., Bouvaist, H., Dauphin, C., Picard, F., Bulifon, S., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00116313 · Cited by 382
Cited by
Items 701–739 of 739
Ahmed, A. (2025) · Lund University Publications (Lund University)
Murta, M. D. S., Baisch, C. W., Silva, T. P. D. C. E., Lobo, S. L. C. B., Ribeiro, M. C. S. D. M. T., & Waetge, D. (2025) · Revista Pulmão · doi:10.63483/rp.v33i4.284
Wei, Q., Zhang, Y., Dai, J., Shan, L., Gong, H., Zhang, Y., Tang, Y., Li, D., Li, L., Sun, X., et al. (2025) · Clinical Rheumatology · doi:10.1007/s10067-025-07879-x
“About 70% of the patients met the criteria of intermediate risk at baseline, and 60% of them were still in this embarrassing stratification during the follow-up [2, 3].”
Gerson, R. B. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Castanha, M. J. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Bernardi, P. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Onkolojik Tedaviye Bağlı Pulmoner Hipertansiyonun Patofizyolojisi ve Klinik Tanısı
Şekerci, S. S. (2021) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.42.c4247
Scelsi, L., Badagliacca, R., D’Alto, M., Acquaro, M., Ameri, P., Argiento, P., Brunetti, N. D., Casu, G., Cedrone, N., Confalonieri, P., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvaf012
Self-citationLailani, M. (., Mamudi, C. O., Wahyudi, W. (., Nurdin, N. H. (., Suparto, S. (., Ginanjar, R. (., Judha, M. (., Lilyana, M. T. (., Irvan, I. (., Fathlina, F. (., et al. (2025) · Neliti
Padervinskienė, L. (2020) · Lithuanian University of Health Sciences
Liu, B., Yan, W., Chen, Y., Zhang, H., Yang, B., Zeng, Q., Liang, Y., Niu, L., Tian, Y., Zhao, Q., et al. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70260
Muñoz, A. R. L. (2023) · Repositorio CES
Mogollón-Vargas, J. M. (2020) · Universidad Industrial de Santander
Costanza, L., Stead, T. S., Joyce, M. F., Maslow, M., & Maslow, A. D. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.03.012
Gómez, J. I. G. (2022) · Investigative News in Education (Universidad de Costa Rica)
Calabrò, G. E., de Belvis, A. G., Bert, F., Moro, G. L., Scaioli, G., D’Ambrosio, F., Donno, R. D., Scarfagna, C., Ricciardi, R., Vizza, D., et al. (2026) · Journal of preventive medicine and hygiene · doi:10.82082/2421-4248/jpmh2026.67.1s1
Guía de Práctica Clínica para el diagnostico y seguimiento de la Hipertensión arterial pulmonar
(IETSI), S. S. E. S. (. I. D. E. D. T. E. S. E. I. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Mady, A. F., Soliman, Y. M. A., Tawfik, N. R., Refaat, H. E., & Abdelfattah, M. T. (2026) · Egyptian Journal of Bronchology · doi:10.1186/s43168-026-00572-w
Ruopp, N. F., Farber, H. W., Rahman, M., Kapur, N. K., & Safdar, Z. (2026) · Cardiology Research · doi:10.14740/cr2225
PRECISÃO NA HIPERTENSÃO PULMONAR: DA RECONFIGURAÇÃO VASCULAR À INTERVENÇÃO TERAPÊUTICA
OLIVEIRA, A. F. D. S., Leão, C. E. S., dos Anjos, L. M., Neto, S. D. A. E. S., Galiaço, Í. N., Silva, R. A. G. E., & Bentes, C. G. (2026) · EPITAYA eBooks · doi:10.47879/ed.ep.20260415p57
Dusík, M., Havránek, Š., Fingrová, Z., Jansa, P., Ambrož, D., Dytrych, V., Skála, T., Hutyra, M., Přeček, J., Reichenbach, A., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1826752
“Although the original trial excluded patients with isolated post-capillary PH, it included patients with idiopathic PAH, PH associated with lung disease, and chronic thromboembolic PH.”
InfluentialHoyer, C. F. (2026) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Coronel, M. L., Sorasio, G., Casas, J. P., Lema, L., Lescano, A. J., Cáneva, J., Echazarreta, D. F., Smith, C., Naval, N., Escalante, J. P., et al. (2026) · Revista de la Federación Argentina de Cardiología · doi:10.63600/54wc1789
Cause of death in a contemporary cohort of patients with pulmonary arterial hypertension
Papadopoulos, G. E., Arvanitaki, A., Ziampa, K., Mouratoglou, S., Chrysochoidis‐Trantas, T., Simitsis, P., Demerouti, E., Karyofillis, P., Tsiapras, D. P., Frogoudaki, A., et al. (2026) · European Heart Journal - Valvular and Structural Heart Disease · doi:10.1093/ehjvshd/xwag078
Factors influencing treatment decisions in patients with pulmonary arterial hypertension
Klose, H. F. E., Roitenberg, A., & Kronberg, K. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2893-7266
Krämer, M., & Kramer, T. (2026) · Scientific Reports · doi:10.1038/s41598-026-70904-9
Self-citationThe Effect of Pulmonary Hypertension on Mortality of Heart Failure Patients in a Nigerian Population
Ogbomo, A., & Obasohan, A. (2025) · Nigerian Journal of Medical and Dental Education
Pulmonary artery hypertension in systemic lupus erythematous (Thai)
Sirichotti, K., & O-charoen, P. (2026) · Thai Journal of Rheumatology
Antithrombotic Therapy Use in Children With Pulmonary Hypertension
O’Neil, M. J., Sleeper, L. A., Varghese, N. P., Critser, P. J., Austin, E. D., Avitabile, C. M., Bates, A., Rosenzweig, E. B., Byrd, C. E., Evers, P. D., et al. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70418
Krämer, M., & Kramer, T. (2026) · JMIR Medical Informatics · doi:10.2196/97372
Self-citationTokgöz, H. C., Kültürsay, B., Tanyeri, S., Sırma, D., Buluş, Ç., Kovanci, T., Kara, M., Atıcı, Ş. Z., Cicek, S. N., Çağlıyan, Ç. E., et al. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70412
Real World, Very-Long Term Survival of Incident Patients with Pulmonary Hypertention
Festas, T. C. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Breakthroughs in the Pathological Mechanism and Comprehensive Management of Pulmonary Hypertension
Zhou, K., Gong, Y., Zhang, J., Chen, D., Liu, Y., & Xu, Z. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm50716
Management of Arrhythmias in Acute and Intensive Care Settings
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-9001-0
Remiszewski, P., Pędzińska-Betiuk, A., Mińczuk, K., Schlicker, E., Klimek, J., Dzięcioł, J., & Malinowska, B. (2022) · doi:10.3389/fphar.2022.965613.s001
Lokhorst, C., van der Werf, S., Berger, R. M. F., & Douwes, J. M. (2022) · doi:10.3389/fcvm.2022.1035453.s001
Lai, J., Zhao, J., Li, K., Qin, X., Wang, H., Tian, Z., Wang, Q., Li, M., Guo, X., Liu, Y., et al. (2022) · doi:10.3389/fcvm.2022.872795.s001
Metadata
- Authors
- Hoeper, M. M., Kramer, T., Pan, Z., Eichstaedt, C. A., Spiesshoefer, J., Benjamin, N., Olsson, K. M., Meyer, K., Vizza, C. D., Vonk-Noordegraaf, A., Distler, O., Opitz, C., Gibbs, J. S. R., Delcroix, M., Ghofrani, H. A., Huscher, D., Pittrow, D., Rosenkranz, S., & Grünig, E.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- University of Cologne (DE)
- University Hospital Heidelberg (DE)
- Heinrich Heine University Düsseldorf (DE)
- Sapienza University of Rome (IT)
- University Hospital Zurich (CH)
- DRK Kliniken Berlin (DE)
- Imperial College London (GB)
- Universitair Ziekenhuis Leuven (BE)
- Justus-Liebig-Universität Gießen (DE)
- Technische Universität Dresden (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-08
- Volume
- 50
- Issue
- 2
- Pages
- 1700740
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2743897368
- Cited by
- 660
- References
- 21
- Citations by year
- 2026: 21 · 2025: 52 · 2024: 74 · 2023: 84 · 2022: 101 · 2021: 111 · 2020: 92 · 2019: 63 · 2018: 53 · 2017: 8
- FWCI
- 48.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- GlaxoSmithKline
- German Centre of Lung Research
- Bayer
- Actelion Pharmaceuticals
- Deutsche Forschungsgemeinschaft (HO 1599/2-1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, mortality prediction, risk stratification, one-year mortality, functional class, 6-minute walk distance, brain natriuretic peptide, right atrial pressure, cardiac index, mixed venous oxygen saturation
- MeSH terms
- Walk Test, Adult, Aged, Aged, 80 and over, Europe, Female, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Prospective Studies, Registries, Severity of Illness Index, Practice Guidelines as Topic, Risk Assessment, Natriuretic Peptide, Brain, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.